Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H13NO7P2.2Na |
| Molecular Weight | 307.0863 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].CN(C)CCC(O)(P(O)([O-])=O)P(O)([O-])=O
InChI
InChIKey=JFGHPLSPUGOSLV-UHFFFAOYSA-L
InChI=1S/C5H15NO7P2.2Na/c1-6(2)4-3-5(7,14(8,9)10)15(11,12)13;;/h7H,3-4H2,1-2H3,(H2,8,9,10)(H2,11,12,13);;/q;2*+1/p-2
| Molecular Formula | C5H13NO7P2 |
| Molecular Weight | 261.1067 |
| Charge | -2 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Olpadronate, a nitrogenated bisphosphonate that can inhibit bone resorption. Although it shares the therapeutic and pharmacological properties of pamidronate and alendronate, it has a greater dosage amplitude, more predictable effects, and greater digestive tolerability than other bisphosphates. Clinical trials have shown that the oral olpadronate was well tolerated and effective in the treatment of Paget's disease. In addition, the drug is ongoing in phase II clinical trials in the Netherlands. This clinical trial has to assess the efficacy of the intravenous drug in decreasing the average back pain intensity from baseline.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Treatment of Paget's disease with olpadronate. Its efficacy in partial responders to oral pamidronate]. | 1997 |
|
| Bisphosphonates for Paget's disease of bone in adults. | 2017 Dec 1 |
|
| Interventions for Improving Bone Mineral Density and Reducing Fracture Risk in Osteogenesis Imperfecta: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials. | 2018 |
Sample Use Guides
Paget's disease: olpadronate was given orally in doses of 100 to 200 mg/day. Initial dose and/or increment of the dose during treatment were decided accordingly to the biochemical response
Olpadronate intra venous in chronic low back pain: 20 mg and 40 mg
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:54:00 GMT 2023
by
admin
on
Fri Dec 15 17:54:00 GMT 2023
|
| Record UNII |
G90M9V9GMQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30153250
Created by
admin on Fri Dec 15 17:54:00 GMT 2023 , Edited by admin on Fri Dec 15 17:54:00 GMT 2023
|
PRIMARY | |||
|
121368-58-9
Created by
admin on Fri Dec 15 17:54:00 GMT 2023 , Edited by admin on Fri Dec 15 17:54:00 GMT 2023
|
PRIMARY | |||
|
G90M9V9GMQ
Created by
admin on Fri Dec 15 17:54:00 GMT 2023 , Edited by admin on Fri Dec 15 17:54:00 GMT 2023
|
PRIMARY | |||
|
198715
Created by
admin on Fri Dec 15 17:54:00 GMT 2023 , Edited by admin on Fri Dec 15 17:54:00 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
